BioSpace News Archive

Today announced it will report its financial results for the fourth quarter and year ended December 31, 2019 after the stock market closes on Wednesday, March 11, 2020.

Q4 2019 DecisionDx-Melanoma test report volume increased 37% compared to Q4 2018

Dr. Ellison has held leadership positions in both emerging biotechnology and large pharmaceutical companies for more than four decades.

Alderaan Biotechnology, a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer, announces today the successful completion of a Series A funding of €18.5M ($20.7M) from investors Advent France Biotechnology (AFB) and Medicxi.

Novelion Therapeutics Inc. announced the definitive date for commencement of implementation of the Company’s voluntary liquidation as 5:00 p.m. Pacific Time on January 16, 2020.

The Company’s research and development priorities for its investigational molecules in 2020 are highlighted below.

On the call, Cerner will discuss its results and outlook and answer questions from the investment community.

Minoryx Therapeutics, a company that specializes in the development of innovative treatments for orphan Central Nervous System (CNS) diseases, today announces that its lead drug candidate leriglitazone (MIN-102) has been granted fast track designation by the US Food and Drug Administration (FDA) for the treatment of all forms of X-linked adrenoleukodystrophy (X-ALD), including adrenomyeloneuropathy (AMN) and childhood cerebral ALD (cALD).

Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6

Dr. Cui will serve as a consultant and support the company during a transition period until June 30, 2020